Advertisement

Oncology Drug Therapy: Cardiotoxicity and the Discipline of Cardio-oncology

  • J. Rick Turner
  • Dilip R. Karnad
  • Snehal Kothari
Chapter

Abstract

The three preceding chapters, which comprise Part IV of this book, discussed topics falling within the domain of proarrhythmic cardiac safety. As we move into Part V, attention now broadens to other domains within the field of cardiovascular safety. This chapter addresses cardiotoxicity considerations in the therapeutic use of oncologic agents. The construct and employment of benefit–risk assessments have been discussed in several contexts in previous chapters. As we move into discussions related to the therapeutic use of drugs that have received marketing approval, the observation by Garattini (2010) that “drug authorization, prescription, and utilization are all based on benefit-risk assessment” provides an integrated perspective on this topic.

Keywords

Left Ventricular Ejection Fraction Arsenic Trioxide Oncologic Drug Cardiovascular Damage Receive Marketing Approval 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Alexander J, Dainiak N, Berger HJ et al (1979) Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300:278–283PubMedCrossRefGoogle Scholar
  2. ALLHAT Collaborative Research Group (2000) Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283:1967–75CrossRefGoogle Scholar
  3. Amini-Khoei H, Hosseini MJ, Momeny M, et al (2016) Morphine attenuated the cytotoxicity induced by arsenic trioxide in H9c2 cardiomyocytes. Biol Trace Elem Res [Epub ahead of print]Google Scholar
  4. Blaes AH, Rehman A, Vock DM et al (2015) Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy. Vasc Health Risk Manag 11:591–594PubMedPubMedCentralCrossRefGoogle Scholar
  5. Cardinale D, Bacchiani G, Beggiato M, Colombo A, Cipolla CM (2013) Strategies to prevent and treat cardiovascular risk in cancer patients. Semin Oncol 40:186–198PubMedCrossRefGoogle Scholar
  6. Cardinale D, Colombo A, Bacchiani G et al (2015) Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131:1891–1998CrossRefGoogle Scholar
  7. Christenson ES, James T, Agrawal V, Park BH (2015) Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clin Biochem 48:223–235PubMedCrossRefGoogle Scholar
  8. Christian JB, Finkle JK, Ky B et al (2012) Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction. Am Heart J 164:846–855PubMedPubMedCentralCrossRefGoogle Scholar
  9. Curigliano G, Cardinale D, Suter T, ESMO Guidelines Working Group et al (2012) Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 23(Suppl 7):155–166Google Scholar
  10. Curigliano G, Cardinale D, Dent S et al (2016) Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin [Epub ahead of print]Google Scholar
  11. Doxorubicin Package Insert. Available at: https://www.doxil.com/shared/product/doxil/doxil-prescribing-information.pdf Accessed 8 Mar 2016
  12. Ewer MS, Lenihan DJ (2008) Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol 26:1201–1203PubMedCrossRefGoogle Scholar
  13. Ferri N, Siegl P, Corsini A et al (2013) Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. Pharmacol Ther 138:470–484PubMedCrossRefGoogle Scholar
  14. Florea VG, Anand IS (2012) Biomarkers. Heart Fail Clin 8:207–24PubMedCrossRefGoogle Scholar
  15. Garattini S (2010) Evaluation of benefit-risk. Pharmacoeconomics 28:981–986PubMedCrossRefGoogle Scholar
  16. Gottdiener JS, Bednarz J, Devereux R, American Society of Echocardiography et al (2004) American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr 17:1086–1119Google Scholar
  17. Grossman E, Messerli FH (2012) Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 125:14–22PubMedCrossRefGoogle Scholar
  18. Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253–259CrossRefGoogle Scholar
  19. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRefGoogle Scholar
  20. Kozloff M, Yood MU, Berlin J et al (2009) Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 14:862–870PubMedCrossRefGoogle Scholar
  21. Lenihan DJ, Cardinale DM (2012) Late cardiac effects of cancer treatment. J Clin Oncol 30:3657–3664PubMedCrossRefGoogle Scholar
  22. Lenihan DJ, Cardinale D, Cipolla CM (2010) The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. Prog Cardiovasc Dis 53:88–93PubMedCrossRefGoogle Scholar
  23. Lipshultz SE, Colan SD, Gelber RD et al (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808–815PubMedCrossRefGoogle Scholar
  24. Morrow DA, Cannon CP, Jesse RL et al (2007) National Academy Of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 115:e356–e375PubMedCrossRefGoogle Scholar
  25. Newby LK, Rodriguez I, Finkle J et al (2011) Troponin measurements during drug development: considerations for monitoring and management of potential toxicity. Am Heart J 162:64–73PubMedCrossRefGoogle Scholar
  26. O’Brien E, Turner JR (2013) Assessing blood pressure responses to noncardiovascular drugs: the beneficial role of ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) 15:55–62CrossRefGoogle Scholar
  27. Pennell DJ, Sechtem UP, Higgins CB et al (2004) Clinical indications for cardiovascular magnetic resonance (CMR): consensus panel report. Eur Heart J 25:1940–1965PubMedCrossRefGoogle Scholar
  28. Pituskin E (2015) Primary results of the MANTICORE randomized, controlled trial. Paper presented at San Antonio Breast Cancer Symposium. Abstract S1-05, 9 December 2015Google Scholar
  29. Raschi E, Vasina V, Ursino MG et al (2010) Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy. Pharmacol Ther 125:196–218PubMedCrossRefGoogle Scholar
  30. Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD (2010) Hypertension induced by VEGF signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol 30:591–601PubMedPubMedCentralCrossRefGoogle Scholar
  31. Rowland JH, Kent EE, Forsythe LP et al (2013) Cancer survivorship research in Europe and the United States: where have we been, where are we going, and what can we learn from each other? Cancer 119(Suppl 11):2094–2108PubMedPubMedCentralCrossRefGoogle Scholar
  32. Rutkowski P, Stępniak J (2016) The safety of regorafenib for the treatment of gastrointestinal stromal tumors. Expert Opin Drug Saf 15:105–116PubMedCrossRefGoogle Scholar
  33. Sager P, Heilbraun J, Turner JR et al (2013) Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium. Am Heart J 165:477–488PubMedCrossRefGoogle Scholar
  34. Schlitt A, Jordan K, Vordermark D et al (2014) Cardiotoxicity and oncological treatments. Dtsch Arztebl Int 111:161–168PubMedPubMedCentralGoogle Scholar
  35. Seicean S, Seicean A, Alan N et al (2013) Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail 6:420–426PubMedCrossRefGoogle Scholar
  36. Small HY, Montezano AC, Rios FJ et al (2014) Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. Can J Cardiol 30:534–543PubMedCrossRefGoogle Scholar
  37. Smith TA, Phyu SM, Akabuogu EU (2016) Effects of administered cardioprotective drugs on treatment response of breast cancer cells. Anticancer Res 36:87–93PubMedCrossRefGoogle Scholar
  38. Steingart RM, Bakris GL, Chen HX et al (2012) Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J 163:156–163PubMedCrossRefGoogle Scholar
  39. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy ML (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672–1677PubMedCrossRefGoogle Scholar
  40. Suter TM, Ewer MS (2013) Cancer drugs and the heart: importance and management. Eur Heart J 34:1102–1111PubMedCrossRefGoogle Scholar
  41. Tashakori Beheshti A, Mostafavi Toroghi H, Hosseini G et al (2016) Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial. Cardiology 134:47–53PubMedCrossRefGoogle Scholar
  42. Thiene G, Corrado D, Basso C (2008) Revisiting definition and classification of cardiomyopathies in the era of molecular medicine. Eur Heart J 29:144–146PubMedCrossRefGoogle Scholar
  43. Turner JR, Durham TA (2009) Integrated cardiac safety: assessment methodologies for noncardiac drugs in discovery, development, and postmarketing surveillance. Wiley, HobokenGoogle Scholar
  44. Turner JR, Panicker GK, Karnad DR et al (2014) Cardiovascular safety monitoring during oncology drug development and therapy. Am J Ther 21:512–522PubMedCrossRefGoogle Scholar
  45. Wallace KB, Hausner E, Herman E et al (2004) Serum troponins as biomarkers of drug-induced cardiac toxicity. Toxicol Pathol 32:106–121PubMedCrossRefGoogle Scholar
  46. Wu S, Chen JJ, Kudelka A et al (2008) Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 9:117–123PubMedCrossRefGoogle Scholar
  47. Yancy CW, Jessup M, Bozlurt B et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62:e147–e239PubMedCrossRefGoogle Scholar
  48. Yusuf SW, Ilias-Khan NA, Durand JB (2011) Chemotherapy-induced cardiomyopathy. Expert Rev Cardiovasc Ther 9:231–243PubMedCrossRefGoogle Scholar
  49. Zhu X, Stergiopoulos K, Wu S (2009) Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 48:9–17PubMedCrossRefGoogle Scholar

Further Reading

  1. Akman T, Erbas O, Akman L, Yilmaz AU (2014) Prevention of pazopanib-induced prolonged cardiac repolarization and proarrhythmic effects. Arq Bras Cardiol 103:403–409PubMedPubMedCentralGoogle Scholar
  2. Angsutararux P, Luanpitpong S, Issaragrisil S (2015) Chemotherapy-induced cardiotoxicity: overview of the roles of oxidative stress. Oxid Med Cell Longev 2015:795602PubMedPubMedCentralCrossRefGoogle Scholar
  3. Aroldi F, Prochilo T, Bonini E, Zaniboni A (2016) QT prolongation and anticancer drugs: is it a cardiologist’s worry? The oncologist’s point of view. Rev Recent Clin Trials [Epub ahead of print]Google Scholar
  4. Barac A, Lynce F, Smith KL et al (2016) Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines. Breast Cancer Res Treat 155:285–293PubMedCrossRefGoogle Scholar
  5. Barac A, Murtagh G, Carver JR et al (2015) Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol 65:2739–2746PubMedPubMedCentralCrossRefGoogle Scholar
  6. Bellinger AM, Arteaga CL, Force T et al (2015) Cardio-oncology: how new targeted cancer therapies and precision medicine can inform cardiovascular discovery. Circulation 132:2248–2258PubMedPubMedCentralCrossRefGoogle Scholar
  7. Bhave M, Akhter N, Rosen ST (2014) Cardiovascular toxicity of biologic agents for cancer therapy. Oncology (Williston Park) 28:482–490Google Scholar
  8. Blaes AH, Rehman A, Vock DM et al (2015) Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy. Vasc Health Risk Manag 11:591–594PubMedPubMedCentralCrossRefGoogle Scholar
  9. Bloom MW, Hamo CE, Cardinale D et al (2016) Cancer therapy-related cardiac dysfunction and heart failure: Part 1: definitions, pathophysiology, risk factors, and imaging. Circ Heart Fail 9:e002661PubMedPubMedCentralCrossRefGoogle Scholar
  10. Blumenthal GM, Cortazar P, Zhang JJ et al (2012) FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. Oncologist 17:1108–1113PubMedPubMedCentralCrossRefGoogle Scholar
  11. Bodai BI, Tuso P (2015) Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm J 19:48–79PubMedPubMedCentralCrossRefGoogle Scholar
  12. Braddock M, Heilbraun J, Mendzelevski B (2013) Cardiovascular safety and hemodynamic considerations in oncology drug development - webinar highlights October 10th 2012. Expert Opin Drug Saf 12:783–791PubMedCrossRefGoogle Scholar
  13. Cardinale D, Colombo A, Lamantia G et al (2008) Cardio-oncology: a new medical issue. Ecancermedicalscience 2:126PubMedPubMedCentralGoogle Scholar
  14. Cardinale D, Colombo A, Lamantia G et al (2010) Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55:213–220PubMedCrossRefGoogle Scholar
  15. Chaudry M, Banchs J, Chavez-MacGregor M (2016) Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker? Biomark Med 10:315–328Google Scholar
  16. Chen CL (2015) Cardiovascular prevention in the cancer survivor. Curr Atheroscler Rep 17:484PubMedCrossRefGoogle Scholar
  17. Chow EJ, Chen Y, Kremer LC et al (2015) Individual prediction of heart failure among childhood cancer survivors. J Clin Oncol 33:394–402PubMedCrossRefGoogle Scholar
  18. Christensen JF, Bandak M, Campbell A, Jones LW, Højman P (2015) Treatment-related cardiovascular late effects and exercise training countermeasures in testicular germ cell cancer survivorship. Acta Oncol 54:592–599PubMedPubMedCentralCrossRefGoogle Scholar
  19. Christenson ES, James T, Agrawal V, Park BH (2015) Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clin Biochem 48:223–235PubMedCrossRefGoogle Scholar
  20. Conway A, McCarthy AL, Lawrence P, Clark RA (2015) The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review. BMC Cancer 15:366PubMedPubMedCentralCrossRefGoogle Scholar
  21. Cummins M, Pavlakis N (2013) The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events. Ther Adv Med Oncol 5:286–300PubMedPubMedCentralCrossRefGoogle Scholar
  22. D’Amore C, Gargiulo P, Paolillo S et al (2014) Nuclear imaging in detection and monitoring of cardiotoxicity. World J Radiol 6:486–492PubMedPubMedCentralCrossRefGoogle Scholar
  23. de Vries Schultink AH, Suleiman AA, Schellens JH, Beijnen JH, Huitema AD (2016) Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment. Eur J Clin Pharmacol 72:645–653Google Scholar
  24. Denlinger CS, Carlson RW, Are M et al (2014) Survivorship: introduction and definition. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 12:34–45PubMedPubMedCentralCrossRefGoogle Scholar
  25. Ederhy S, Izzedine H, Massard C et al (2011) Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol 80:369–379PubMedCrossRefGoogle Scholar
  26. Ewer MS, Ewer SM (2015) Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 12:547–558PubMedCrossRefGoogle Scholar
  27. Ewer M, Gianni L, Pane F et al (2014) Report on the international colloquium on cardio-oncology (Rome, 12-14 march 2014). Ecancermedicalscience 8:433PubMedPubMedCentralGoogle Scholar
  28. Eschenhagen T, Force T, Ewer MS et al (2011) Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 13:1–10PubMedCrossRefGoogle Scholar
  29. Faruque LI, Lin M, Battistella M et al (2014) Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer. PLoS One 9:e101145PubMedPubMedCentralCrossRefGoogle Scholar
  30. Fradley MG, Moslehi J (2015) QT prolongation and oncology drug development. Card Electrophysiol Clin 7:341–355PubMedCrossRefGoogle Scholar
  31. Ghatalia P, Je Y, Kaymakcalan MD, Sonpavde G, Choueiri TK (2015) QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer 112:296–305PubMedCrossRefGoogle Scholar
  32. Ghigo A, Li M, Hirsch E (2016) New signal transduction paradigms in anthracycline-induced cardiotoxicity. Biochim Biophys Acta 1863:1916–1925Google Scholar
  33. Gulati G, Zhang KW, Scherrer-Crosbie M, Ky B (2014) Cancer and cardiovascular disease: the use of novel echocardiography measures to predict subsequent cardiotoxicity in breast cancer treated with anthracyclines and trastuzumab. Curr Heart Fail Rep 11:366–373PubMedPubMedCentralCrossRefGoogle Scholar
  34. Hahn VS, Lenihan DJ, Ky B (2014) Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc 3:e000665PubMedPubMedCentralCrossRefGoogle Scholar
  35. Hamo CE, Bloom MW (2015) Getting to the heart of the matter: an overview of cardiac toxicity related to cancer therapy. Clin Med Insights Cardiol 9(Suppl 2):47–51PubMedPubMedCentralGoogle Scholar
  36. Hamo CE, Bloom MW, Cardinale D et al (2016) Cancer therapy-related cardiac dysfunction and heart failure: Part 2: prevention, treatment, guidelines, and future directions. Circ Heart Fail 9:e002843PubMedPubMedCentralCrossRefGoogle Scholar
  37. Herman E, Knapton A, Zhang J et al (2014) The utility of serum biomarkers to detect myocardial alterations induced by imatinib in rats. Pharmacol Res Perspect 2:e00015PubMedPubMedCentralCrossRefGoogle Scholar
  38. Herrmann J, Lerman A, Sandhu NP et al (2014) Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc 89:1287–1306PubMedPubMedCentralCrossRefGoogle Scholar
  39. Iliescu CA, Grines CL, Herrmann J et al (2016) SCAI expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of India, and Sociedad Latino Americana de Cardiologia Intervencionista). Catheter Cardiovasc Interv 87:E202–E223Google Scholar
  40. Jang S, Zheng C, Tsai HT et al (2016) Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma. Cancer 122:124–130PubMedCrossRefGoogle Scholar
  41. Jensen BC, McLeod HL (2013) Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. Pharmacogenomics 14:205–213PubMedPubMedCentralCrossRefGoogle Scholar
  42. Kaneko S, Tham EB, Haykowsky MJ et al (2016) Impaired left ventricular reserve in childhood cancer survivors treated with anthracycline therapy. Pediatr Blood Cancer 63:1086–1090Google Scholar
  43. Kirkham AA, Davis MK (2015) Exercise prevention of cardiovascular disease in breast cancer survivors. J Oncol 2015:917606PubMedPubMedCentralCrossRefGoogle Scholar
  44. Kleiman R, Litwin J, Morganroth J (2016) Benefits of centralized ECG reading in clinical oncology studies. Ther Innov Regul Sci 50:123–129CrossRefGoogle Scholar
  45. Kloth JS, Pagani A, Verboom MC et al (2015) Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br J Cancer 112:1011–1016PubMedPubMedCentralCrossRefGoogle Scholar
  46. Korzeniowska K, Jankowski J, Cieślewicz A, Jabłecka A (2015) Current approach for detection of sub-clinical left ventricular dysfunction associated with chemotherapy. Pharmacol Rep 67:1098–1102PubMedCrossRefGoogle Scholar
  47. Lamore SD, Kamendi HW, Scott CW, Dragan YP, Peters MF (2013) Cellular impedance assays for predictive preclinical drug screening of kinase inhibitor cardiovascular toxicity. Toxicol Sci 135:402–413PubMedCrossRefGoogle Scholar
  48. Lancellotti P, Anker SD, Donal E et al (2015) EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry): EURObservational Research Program of the European Society of Cardiology. Eur Heart J Cardiovasc Imaging 16:466–470PubMedCrossRefGoogle Scholar
  49. Lankhorst S, Kappers MH, van Esch JH, Danser AH, van den Meiracker AH (2013) Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1. J Hypertens 31:444–454PubMedCrossRefGoogle Scholar
  50. Lankhorst S, Baelde HJ, Kappers MH et al (2015) Greater sensitivity of blood pressure than renal toxicity to tyrosine kinase receptor inhibition with sunitinib. Hypertension 66:543–549PubMedCrossRefGoogle Scholar
  51. Lankhorst S, Kappers MH, van Esch JH et al (2014) Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study. Hypertension 64:1282–1289PubMedCrossRefGoogle Scholar
  52. Le DL, Cao H, Yang LX (2014) Cardiotoxicity of molecular-targeted drug therapy. Anticancer Res 34:3243–3249PubMedGoogle Scholar
  53. Lenihan DJ (2014) Reversibility of effectively treated chemotherapy-related heart failure: raising our awareness and a call to action for cardiology. J Card Fail 20:159–160PubMedCrossRefGoogle Scholar
  54. Lenihan DJ, Kowey PR (2013) Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist 18:900–908PubMedPubMedCentralCrossRefGoogle Scholar
  55. Lenihan DJ, Westcott G (2015) Cardio-oncology: a tremendous opportunity to improve patient care. Future Oncol 11:2007–2010PubMedCrossRefGoogle Scholar
  56. Lenihan DJ, Cardinale DM (2012) Late cardiac effects of cancer treatment. J Clin Oncol 30:3657–3664PubMedCrossRefGoogle Scholar
  57. Lenihan DJ, Oliva S, Chow EJ, Cardinale D (2013) Cardiac toxicity in cancer survivors. Cancer 119(Suppl 11):2131–2142PubMedCrossRefGoogle Scholar
  58. Lipshultz SE, Franco VI, Miller TL, Colan SD, Sallan SE (2015) Cardiovascular disease in adult survivors of childhood cancer. Annu Rev Med 66:161–176PubMedPubMedCentralCrossRefGoogle Scholar
  59. Madan R, Benson R, Sharma DN, Julka PK, Rath GK (2015) Radiation induced heart disease: pathogenesis, management and review literature. J Egypt Natl Canc Inst 27:187–193PubMedCrossRefGoogle Scholar
  60. Maharsy W, Aries A, Mansour O, Komati H, Nemer M (2014) Ageing is a risk factor in imatinib mesylate cardiotoxicity. Eur J Heart Fail 16:367–376PubMedPubMedCentralCrossRefGoogle Scholar
  61. Mallarkey G, Mangoni AA (2015) Targeting precision medicine toxicity: recent developments. Ther Adv Drug Saf 6:4–14PubMedPubMedCentralCrossRefGoogle Scholar
  62. Mantarro S, Rossi M, Bonifazi M et al (2016) Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer. Intern Emerg Med 11:123–140PubMedCrossRefGoogle Scholar
  63. Marmagkiolis K, Finch W, Tsitlakidou D et al (2016) Radiation toxicity to the cardiovascular system. Curr Oncol Rep 18:15PubMedCrossRefGoogle Scholar
  64. McCabe MS, Bhatia S, Oeffinger KC et al (2013) American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. J Clin Oncol 31:631–640PubMedPubMedCentralCrossRefGoogle Scholar
  65. Molinaro M, Ameri P, Marone G et al (2015) Recent advances on pathophysiology, diagnostic and therapeutic insights in cardiac dysfunction induced by antineoplastic drugs. Biomed Res Int 2015:138–148CrossRefGoogle Scholar
  66. Mozdzanowska D, Woźniewski M (2015) Radiotherapy and anthracyclines: cardiovascular toxicity. Contemp Oncol (Pozn) 19:93–97Google Scholar
  67. Naumann D, Rusius V, Margiotta C et al (2013) Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer. Anticancer Res 33:1717–1720PubMedGoogle Scholar
  68. Nekhlyudov L, Aziz NM, Lerro C, Virgo KS (2014) Oncologists’ and primary care physicians’ awareness of late and long-term effects of chemotherapy: implications for care of the growing population of survivors. J Oncol Pract 10:e29–e36PubMedCrossRefGoogle Scholar
  69. Nekhlyudov L, Wenger N (2014) Institute of medicine recommendations for improving the quality of cancer care: what do they mean for the general internist? J Gen Intern Med 29:1404–1409PubMedPubMedCentralCrossRefGoogle Scholar
  70. Nguyen KL, Alrezk R, Mansourian PG et al (2015) The crossroads of geriatric cardiology and cardio-oncology. Curr Geriatr Rep 4:327–337PubMedPubMedCentralCrossRefGoogle Scholar
  71. Niraula S, Seruga B, Ocana A et al (2012) The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol 30:3012–3019PubMedCrossRefGoogle Scholar
  72. O’Hare M, Sharma A, Murphy K, Mookadam F, Lee H (2015) Cardio-oncology Part I: chemotherapy and cardiovascular toxicity. Expert Rev Cardiovasc Ther 13:511–518PubMedCrossRefGoogle Scholar
  73. O’Hare M, Murphy K, Mookadam F, Sharma A, Lee H (2015) Cardio-oncology Part II: the monitoring, prevention, detection and treatment of chemotherapeutic cardiac toxicity. Expert Rev Cardiovasc Ther 13:519–527PubMedCrossRefGoogle Scholar
  74. Onitilo AA, Engel JM, Stankowski RV (2014) Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf 5:154–166PubMedPubMedCentralCrossRefGoogle Scholar
  75. Pituskin E, Haykowsky M, Mackey JR et al (2011) Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101–Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer 11:318PubMedPubMedCentralCrossRefGoogle Scholar
  76. Pizzino F, Vizzari G, Qamar R et al (2015) Multimodality imaging in cardio-oncology. J Oncol 2015:263950PubMedPubMedCentralCrossRefGoogle Scholar
  77. Poulin F, Thavendiranathan P (2015) Cardiotoxicity due to chemotherapy: role of cardiac imaging. Curr Cardiol Rep 17:564PubMedCrossRefGoogle Scholar
  78. Rosa GM, Gigli L, Tagliasacchi MI et al (2016) Update on cardiotoxicity of anti-cancer treatments. Eur J Clin Invest 46:264–284PubMedCrossRefGoogle Scholar
  79. Roth GJ, Binder R, Colbatzky F et al (2015) Nintedanib: from discovery to the clinic. J Med Chem 58:1053–1063PubMedCrossRefGoogle Scholar
  80. Runowicz CD, Leach CR, Henry NL et al (2016) American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol 34:611–635PubMedCrossRefGoogle Scholar
  81. Sager PT, Balser B, Wolfson J et al (2015) Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin. Cancer Med 4:1178–1185PubMedPubMedCentralCrossRefGoogle Scholar
  82. Schindler M, Spycher BD, Ammann RA, Swiss Paediatric Oncology Group (SPOG) et al (2016) Cause-specific long-term mortality in survivors of childhood cancer in Switzerland: a population based study. Int J Cancer 139:322–333Google Scholar
  83. Schover LR, van der Kaaij M, van Dorst E et al (2014) Sexual dysfunction and infertility as late effects of cancer treatment. EJC Suppl 12:41–53PubMedPubMedCentralCrossRefGoogle Scholar
  84. Shah RR, Morganroth J (2015) Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on QT interval, left ventricular dysfunction and overall risk/benefit. Drug Saf 38:693–710PubMedCrossRefGoogle Scholar
  85. Skinner M, Philp K, Lengel D et al (2014) The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation. Br J Pharmacol 171:2308–2320PubMedPubMedCentralCrossRefGoogle Scholar
  86. Small HY, Montezano AC, Rios FJ, Savoia C, Touyz RM (2014) Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. Can J Cardiol 30:534–543PubMedCrossRefGoogle Scholar
  87. Srikanthan A, Ethier JL, Ocana A et al (2015) Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study. PLoS One 10:e0122735PubMedPubMedCentralCrossRefGoogle Scholar
  88. Stevens PL, Lenihan DJ (2015) Cardiotoxicity due to chemotherapy: the role of biomarkers. Curr Cardiol Rep 17:603PubMedCrossRefGoogle Scholar
  89. Todaro MC, Oreto L, Qamar R et al (2013) Cardioncology: state of the heart. Int J Cardiol 168:680–687PubMedCrossRefGoogle Scholar
  90. Valachis A, Nilsson C (2015) Cardiac risk in the treatment of breast cancer: assessment and management. Breast Cancer (Dove Med Press) 7:21–35Google Scholar
  91. Valle JW, Faivre S, Hubner RA, Grande E, Raymond E (2014) Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. Cancer Treat Rev 40:1230–1238PubMedCrossRefGoogle Scholar
  92. Varga ZV, Ferdinandy P, Liaudet L, Pacher P (2015) Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol 309:H1453–H1467PubMedPubMedCentralCrossRefGoogle Scholar
  93. Venkatakrishnan K, Friberg LE, Ouellet D et al (2015) Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities. Clin Pharmacol Ther 97:37–54PubMedCrossRefGoogle Scholar
  94. Vijayvergia N, Denlinger CS (2015) Lifestyle factors in cancer survivorship: where we are and where we are headed. Pers Med 5:243–263CrossRefGoogle Scholar
  95. Wickramasinghe CD, Nguyen KL, Watson KE, Vorobiof G, Yang EH (2016) Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity. Future Oncol 12:855–870PubMedCrossRefGoogle Scholar
  96. Wiegers SE (2015) Cardio-oncology and echocardiography: partners in improving patient care. J Am Soc Echocardiogr 28:A15PubMedCrossRefGoogle Scholar
  97. Yamazaki S (2013) Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib. AAPS J 15:354–366PubMedCrossRefGoogle Scholar
  98. Yeboa DN, Evans SB (2016) Contemporary breast radiotherapy and cardiac toxicity. Semin Radiat Oncol 26:71–78PubMedCrossRefGoogle Scholar
  99. Yu AF, Ky B (2016) Roadmap for biomarkers of cancer therapy cardiotoxicity. Heart 102:425–430PubMedCrossRefGoogle Scholar
  100. Xie Y, Collins WJ, Audeh MW et al (2015) Breast cancer survivorship and cardiovascular disease: emerging approaches in cardio-oncology. Curr Treat Options Cardiovasc Med 17:60PubMedCrossRefGoogle Scholar
  101. Xue J, Jiang Z, Qi F et al (2014) Risk of trastuzumab-related cardiotoxicity in early breast cancer patients: a prospective observational study. J Breast Cancer 17:363–369PubMedPubMedCentralCrossRefGoogle Scholar
  102. Zagar TM, Cardinale DM, Marks LB (2016) Breast cancer therapy-associated cardiovascular disease. Nat Rev Clin Oncol 13:172–184PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • J. Rick Turner
    • 1
  • Dilip R. Karnad
    • 2
  • Snehal Kothari
    • 3
  1. 1.Cardiac Safety Services QuintilesDurhamUSA
  2. 2.Research TeamCardiac Safety Services QuintilesMumbaiIndia
  3. 3.Cardiac Safety Services Global HeadCardiac Safety Center of Excellence QuintilesMumbaiIndia

Personalised recommendations